FBM Pharma

FBM Pharma is a clinical-stage biopharmaceutical company based in Taiwan that specializes in the development of innovative small molecule therapeutics and long-acting injectable (LAI) formulations. Utilizing its proprietary In-Situ Forming Depot (ISD) technology platform, the company focuses on addressing unmet needs in central nervous system (CNS) disorders, chronic pain, and oncology. Its lead candidate, ALA-1000, is a long-acting buprenorphine prodrug in Phase 3 development for opioid use disorder, which has been licensed to Indivior in a significant global partnership. The company's pipeline also includes FBM-1001, a multi-kinase inhibitor being evaluated for advanced solid tumors, and ALA-2000 for chronic pain management. FBM Pharma aims to enhance patient compliance and therapeutic efficacy through its advanced drug delivery systems and targeted medicinal chemistry.